Drug General Information
Drug ID	D0G4BR
Former ID	DNC004979
Drug Name	Meglutol
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[527409]
Structure		Download 2D MOL 3D MOL
Formula	C6H10O5
Canonical SMILES	CC(CC(=O)O)(CC(=O)O)O
InChI	1S/C6H10O5/c1-6(11,2-4(7)8)3-5(9)10/h11H,2-3H2,1H3,(H,7,8)(H,9,10)
InChIKey	NPOAOTPXWNWTSH-UHFFFAOYSA-N
CAS Number	CAS 503-49-1
PubChem Compound ID	1662
SuperDrug ATC ID	C10AX05
Target and Pathway
Target(s)	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Target Info	Inhibitor	[527409]
BioCyc Pathway	Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)
	Superpathway of cholesterol biosynthesis
	Mevalonate pathway
KEGG Pathway	Terpenoid backbone biosynthesis
	Metabolic pathways
	Biosynthesis of antibiotics
	AMPK signaling pathway
	Bile secretion
NetPath Pathway	IL5 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
	TSH Signaling Pathway
PANTHER Pathway	Cholesterol biosynthesis
PathWhiz Pathway	Steroid Biosynthesis
WikiPathways	Statin Pathway
	Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
	Activation of Gene Expression by SREBP (SREBF)
	SREBF and miR33 in cholesterol and lipid homeostasis
	Integrated Breast Cancer Pathway
	SREBP signalling
	Cholesterol Biosynthesis
References
Ref 527409	Bioorg Med Chem Lett. 2005 Feb 15;15(4):989-94.Molecular docking of the highly hypolipidemic agent alpha-asarone with the catalytic portion of HMG-CoA reductase.
Ref 527409	Bioorg Med Chem Lett. 2005 Feb 15;15(4):989-94.Molecular docking of the highly hypolipidemic agent alpha-asarone with the catalytic portion of HMG-CoA reductase.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.